反意义疗法:在神经退行性疾病的治疗中,这是一个潜在的突破
Roberta Romano1, Cecilia Bucci1
1Department of Biological and Environmental Sciences and Technologies (DiSTeBA), University of Salento, Lecce, Italy.
Neural regeneration research
|October 20, 2023
概括
反意义疗法为治疗神经退行性疾病提供了一个有希望的,更安全的替代方案,通过针对神经元退化而不会改变基因组. 这篇评论强调了最近的进展和FDA批准的治疗方法.
科学领域:
- 神经学 神经学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经退行性疾病涉及渐进的神经元损失,造成全球健康负担很大.
- 目前的治疗方法缺乏治疗方法,需要新的治疗策略.
- 反意义疗法是潜在的解决方案,因为它们的安全性和非基因组修饰.
研究的目的:
- 审查神经退行性疾病的反感性疗法的最新进展.
- 专注于FDA批准的反感应治疗常见的神经退行性疾病.
主要方法:
- 关于反意义疗法的临床前和临床研究的文献综述.
- 对这些治疗方法的安全性和疗效的最新研究进行分析.
- 对神经退行性疾病的FDA批准的反感觉疗法的识别.
主要成果:
- 反意义疗法在临床前和临床环境中显示出神经退行性疾病治疗的潜力.
- 几种反感疗法已经通过临床试验取得了进展,其中一些获得了FDA的批准.
- 这些疗法为疾病修饰提供了有针对性的方法.
结论:
- 反意义疗法在治疗神经退行性疾病方面取得了重大进展.
- 进一步的研究和开发对于扩大治疗选择至关重要.
- 经FDA批准的反感疗法为患者和医疗保健系统提供了新的希望.
相关概念视频
Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Parkinson's Disease: Overview
567
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
567
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K


